MedDataX Logo

IV Fluids and Post-ERCP Pancreatitis

NCT05211206 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 13000

Last updated 2024-01-09

No results posted yet for this study

Summary

Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).

Conditions

  • ERCP

Interventions

OTHER

IV fluids

Amount of intravenous fluids delivered

Sponsors & Collaborators

  • McGill University

    collaborator OTHER

  • University of Ottawa

    collaborator OTHER

  • Queen's University

    collaborator OTHER

  • Halton Health (Oakville)

    collaborator UNKNOWN

  • Island Health, Victoria, BC

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Nauzer Forbes, MD MSc · University of Calgary

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-10
Primary Completion
2025-12-31
Completion
2026-02-28

Countries

  • Canada

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05211206 on ClinicalTrials.gov